SNOMED CT Case for Investment - Final September 2021 - Flipbook - Page 21
EXECUTIVE SUMMARY
The estimated cost of implementing a SNOMED CT license in the USA for the
15-year study period was USD87M.
Productivity
(Model 1)
validated by
Disease
Prevention
(Model 2)
Patient
Safety
(Model 3)
Data from
Five Studies
Data from
Model 1
Potential mean savings of USD$58.25 billion per year in improved inpatient and outpatient
services.
A reduction of over 1.1 million adverse drug events and 6.4 million bed days, as well as 8,300 deaths
avoided from CPOE use.
BCM &
IRR
(Model 4)
Impact on
GNI
(Model 5)
Over 750,000 reduced bed days, approximately 85,000 reduced workdays missed and over
2,200 deaths avoided from immunizations, and over 3700 deaths avoided and 50,000 lifeyears gained from cancer screening.
A Benefits to Cost Multiple of 1.8 - 4.1 and an Internal Rate of Return for the same
investment of 10-41%. from investing in clinical information systems and interoperability
solutions.
The average annual increase to U.S. GNI as a result of the investments in clinical information
systems and interoperability solutions was 0.23% or USD$30.71 billion.
The estimated cost of
implementing a SNOMED
CT license in the USA for
the 15-year study period
was USD87M.
Using only the
Model 1
cumulative
benefits of
USD$875B the
breakeven
percentage is
0.01%.